DE-ROCKET.CHAT
22.7.2021 14:02:09 CEST | Business Wire | Press release
Rocket.Chat , the leading open-source communication hub, is announcing the release of Catalyst , its new partner program that consolidates all the assets needed to accelerate growth of new and existing partners across the globe.
“Since the beginning we have been working in close collaboration with service and technology providers to deliver increased value to our customers, which naturally led us to clearly understand the key aspects needed to support our partners’ growth throughout their journey and ultimately leverage their ROI through our partnership. Rocket.Chat’s Catalyst materializes these learnings into a journey-based program that will support companies of all sizes that target the same market and want to establish a results-driven, long-lasting relationship with Rocket.Chat,” said Julio Azzini, Global Head of Partnerships at Rocket.Chat.
The pandemic forced businesses around the globe to abruptly adopt the remote work environment, on a never-before-seen scale. This presented a unique opportunity for Rocket.Chat, helping to boost the company’s hyper growth - a trend that is set to continue as evidence mounts that the remote work momentum will not fade away for the foreseeable future. As an open-source business, Rocket.Chat benefits from a strong global footprint across different sectors that, combined with its recent Series A funding round , will accelerate growth and create opportunities for both Rocket.Chat and its partner ecosystem.
“The investment we made to revamp our existing (partner) program reinforces our commitment to our partners and ultimately, to our customers, to better serve them at a local level and on a global scale. Our partner ecosystem plays a crucial role in our go-to-market strategy,” shared Gabriel Engel, co-founder and CEO of Rocket.Chat. “Partners act as our service arm because they are the ones who are implementing strategic projects, scaling our apps and setting up the integrations that enable our customers to personalize and make the most of their Rocket.Chat experience.”
The new program encompasses a self-paced, scalable onboarding process that enables all key roles within a partner organization to sell and deliver projects through the Rocket.Chat partner portal. The robust capabilities of the program increase collaboration between internal teams and external providers to better manage the partner experience and overall journey while working within Rocket.Chat.
“We decided to implement the same training that we provide to our internal team to our partners. We see our partner relationships as a critical part of our company, rather than just a go-to-market channel. On top of all improvements made we have hired a very talented and competent group of professionals, now outfitted with the assets they need to ensure that we are taking our partner program -- and ultimately our partnerships -- to the next level,” added Azzini.
The new partner program operates across three tiers that are organized based on the overall capabilities and contributions of partners across all types of business models. For more information, please visit: www.Rocket.Chat/partners
About Rocket.Chat
Rocket.Chat is used by Audi, Alfa-Bank, Caixa, Daimler, HTC, Intel, Lockheed Martin, Nationwide Insurance, and other enterprises worldwide to control their communication, manage their data, and have their own collaboration platform to improve team productivity. Rocket.Chat users can switch between team chat and video or audio calls with screen sharing for more efficient teamwork. The platform’s open-source foundation empowers enterprises with complete access to the source code so that they can fully customize, extend or add new functionality to meet their unique requirements. Rocket.Chat is now installed on more than 700,000 servers, counts over 12 million users worldwide, and has an active, passionate community of over 800 developer-contributors who help Rocket.Chat’s core team of developers to constantly improve the product.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005172/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom